GoKawiilInsilico's AI-designed lung drug rentosertib shows anti-aging signals in trial
Insilico Medicine's AI-designed drug rentosertib, originally developed to treat idiopathic pulmonary fibrosis, produced unexpected reductions in biological age markers during a phase 2a trial. Researchers reanalyzed blood samples from 42 of 71 Chinese trial participants using six computational aging clocks, finding treated patients showed younger predicted ages after 12 weeks compared to placebo recipients.